Meta-analysis of randomized controlled trials of vancomycin for the treatment of patients with gram-positive infections: Focus on the study design

Mayo Clinic Proceedings

Volumn 87, Issue 4, 2012, Pages 349-363

  Vardakas, Konstantinos Z ^a,b   Mavros, Michael N ^a   Roussos, Nikolaos ^a   Falagas, Matthew E ^a,b,c  

^a ALFA INSTITUTE OF BIOMEDICAL SCIENCES AIBS   (Greece)

^b HENRY DUNANT HOSPITAL   (Greece)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTAROLINE; CEFTOBIPROLE; DALBAVANCIN; DALFOPRISTIN PLUS QUINUPRISTIN; DAPTOMYCIN; ICLAPRIM; LINEZOLID; TEICOPLANIN; TELAVANCIN; TIGECYCLINE; VANCOMYCIN;

ADVERSE OUTCOME; ANTIBIOTIC THERAPY; ARTICLE; BACTEREMIA; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; GRAM POSITIVE INFECTION; HUMAN; INTENTION TO TREAT ANALYSIS; META ANALYSIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MORTALITY; NEPHROTOXICITY; OPEN STUDY; PNEUMONIA; POPULATION RESEARCH; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT INFECTION; SECONDARY INFECTION; SKIN INFECTION; SOFT TISSUE INFECTION; STAPHYLOCOCCUS INFECTION; STUDY DESIGN; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

EID: 84859845244     PISSN: 00256196     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mayocp.2011.12.011     Document Type: Article

References (97)

1. Pallares R, Dick R, Wenzel RP, Adams JR, Nettleman MD. Trends in antimicrobial utilization at a tertiary teaching hospital during a 15-year period (1978-1992). Infect Control Hosp Epidemiol. 1993;14(7):376-382.
2. Lodise TP, Lomaestro B, Graves J, et al. Larger vancomycin doses (≥4 grams/day) are associated with an increased incidence of nephrotoxicity. Antimicrob Agents Chemother. 2008; 52:1330-1336. (Pubitemid 351521995)
3. Levine DP. Vancomycin: a history. Clin Infect Dis. 2006; 42(suppl 1):S5-S12. (Pubitemid 41832060)
4. Rybak MJ, Albrecht LM, Boike SC, Chandrasekar PH. Nephrotoxicity of vancomycin alone and with an aminoglycoside. J Antimicrob Chemother. 1990;25(4):679-687.
5. Rybak M, Lomaestro B, Rotschafer JC, et al. Therapeutic monitoring of vancomycin in adult patients: a consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Am J Health Syst Pharm. 2009; 66(1):82-98.
6. Georges H, Leroy O, Alfandari S, et al. Pulmonary disposition of vancomycin in critically ill patients. Eur J Clin Microbiol Infect Dis. 1997;16(5):385-388. (Pubitemid 27271829)
7. Scheetz MH, Wunderink RG, Postelnick MJ, Noskin GA. Potential impact of vancomycin pulmonary distribution on treatment outcomes in patients with methicillin-resistant Staphylococcus aureus pneumonia. Pharmacotherapy. 2006;26(4):539-550.
8. Tenover FC, Moellering RC Jr. The rationale for revising the Clinical and Laboratory Standards Institute vancomycin minimal inhibitory concentration interpretive criteria for Staphylococcus aureus. Clin Infect Dis. 2007;44(9):1208-1215. (Pubitemid 46651246)
9. Sakoulas G, Moise-Broder PA, Schentag J, Moellering RC Jr, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2004;42(6): 2398-2402. (Pubitemid 38747480)
10. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med. 2006;166(19):2138-2144. (Pubitemid 44631403)
11. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis. 2004;38(3):448-451. (Pubitemid 38200128)
12. Kollef MH. Limitations of vancomycin in the management of resistant staphylococcal infections. Clin Infect Dis. 2007;45(suppl 3):S191-S195. (Pubitemid 47378906)
13. Nishimura RA, Carabello BA, Faxon DP, et al American College of Cardiology/American Heart Association Task Force. ACC/AHA 2008 guideline update on valvular heart disease: focused update on infective endocarditis: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: endorsed by the Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2008;118(8):887-896.
14. Mermel LA, Allon M, Bouza E, et al. Clinical practice guidelines for the diagnosis and management of intravascular catheter-related infection: 2009 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;49(1):1-45.
15. Stevens DL, Bisno AL, Chambers HF, et al Infectious Diseases Society of America. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis. 2005;41(10):1373-1406. (Pubitemid 41581713)
16. American Thoracic Society; Infectious Diseases Society of America. Guidelines for the management of adults with hospital- acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171(4):388-416.
17. Falagas ME, Siempos II, Vardakas KZ. Linezolid versus glycopeptide or beta-lactam for treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials. Lancet Infect Dis. 2008;8(1):53-66. (Pubitemid 351620940)
18. Svetitsky S, Leibovici L, Paul M. Comparative efficacy and safety of vancomycin versus teicoplanin: systematic review and meta-analysis. Antimicrob Agents Chemother. 2009;53(10): 4069-4079.
19. Beibei L, Yun C, Mengli C, Nan B, Xuhong Y, Rui W. Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials. Int J Antimicrob Agents. 2010;35(1):3-12.
20. Rosmarakis ES, Soteriades ES, Vergidis PI, Kasiakou SK, Falagas ME. From conference abstract to full paper: differences between data presented in conferences and journals. FASEB J. 2005;19(7):673-680. (Pubitemid 40617372)
21. Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet. 1998;352(9128):609-613. (Pubitemid 28380142)
22. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109):629-634. (Pubitemid 27387172)
23. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719-748.
24. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177-188. (Pubitemid 17189972)
25. Wilcox MH, Tack KJ, Bouza E, et al. Complicated skin and skin-structure infections and catheter-related bloodstream infections: noninferiority of linezolid in a phase 3 study. Clin Infect Dis. 2009;48(2):203-212.
26. Wunderink RG, Mendelson MH, Somero MS, et al. Early microbiological response to linezolid vs vancomycin in ventilator- associated pneumonia due to methicillin-resistant Staphylococcus aureus. Chest. 2008;134(6):1200-1207.
27. Lin DF, Zhang YY, Wu JF, et al. Linezolid for the treatment of infections caused by Gram-positive pathogens in China. Int J Antimicrob Agents. 2008;32(3):241-249.
28. Pfizer. Linezolid vs vancomycin/cefazolin in the treatment of hemodialysis patients with catheter-related gram-positive bloodstream infections. A5951105. http://www.clinicalstudyresults. org/documents/company- study-2421-0.pdf. Accessed January 13, 2010.
29. Pfizer Linezolid in the treatment of subjects with complicated skin and soft tissue infections proven to be due to methicillin-resistant staphylococcus aureus. A5951002. http://www. clinicalstudyresults.org/documents/company-study- 4375-0. pdf. Accessed January 13, 2010.
30. Kohno S, Yamaguchi K, Aikawa N, et al. Linezolid versus vancomycin for the treatment of infections caused by methicillin- resistant Staphylococcus aureus in Japan. J Antimicrob Chemother. 2007;60(6):1361-1369. (Pubitemid 350168334)
31. Pfizer. Time to efficacy and onset of action of linezolid compared to vancomycin in skin and soft tissue infections. OXAA- 0026-162. http://www.clinicalstudyresults.org/documents/company-study- 1864-0.pdf. Accessed January 13, 2010.
32. Jaksic B, Martinelli G, Perez-Oteyza J, Hartman CS, Leonard LB, Tack KJ. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis. 2006;42(5):597-607. (Pubitemid 43271371)
33. Sharpe JN, Shively EH, Polk HC Jr. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am J Surg. 2005;189(4):425-428. (Pubitemid 40488237)
34. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C; Linezolid CSSTI Study Group. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2005;49(6):2260-2266. (Pubitemid 40734452)
35. Kaplan SL, Afghani B, Lopez P, et al. Linezolid for the treatment of methicillin-resistant Staphylococcus aureus infections in children. Pediatr Infect Dis J. 2003;22(9, suppl):S178-S185. (Pubitemid 37158767)
36. Wunderink RG, Cammarata SK, Oliphant TH, Kollef MH; Linezolid Nosocomial Pneumonia Study Group. Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia. Clin Ther. 2003;25(3):980-992. (Pubitemid 36459702)
37. Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis. 2002; 34(11):1481-1490. (Pubitemid 34553708)
38. Rubinstein E, Cammarata S, Oliphant T, Wunderink R; Linezolid Nosocomial Pneumonia Study Group. Linezolid (PNU- 100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, doubleblind, multicenter study. Clin Infect Dis. 2001;32(3):402-412. (Pubitemid 32173626)
39. Corey GR, Wilcox MH, Talbot GH, Thye D, Friedland D, Baculik T; CANVAS 1 investigators. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65(suppl 4):iv41-iv51.
40. Wilcox MH, Corey GR, Talbot GH, Thye D, Friedland D, Baculik T; CANVAS 2 Investigators. CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65(suppl 4):iv53-iv65.
41. Talbot GH, Thye D, Das A, Ge Y. Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections. Antimicrob Agents Chemother. 2007; 51(10):3612-3616. (Pubitemid 47519351)
42. Noel GJ, Bush K, Bagchi P, Ianus J, Strauss RS. A randomized, double-blind trial comparing ceftobiprole medocaril with vancomycin plus ceftazidime for the treatment of patients with complicated skin and skin-structure infections. Clin Infect Dis. 2008;46(5):647-655. (Pubitemid 351321545)
43. Noel GJ, Strauss RS, Amsler K, Heep M, Pypstra R, Solomkin JS. Results of a double-blind, randomized trial of ceftobiprole treatment of complicated skin and skin structure infections caused by gram-positive bacteria. Antimicrob Agents Chemother. 2008;52(1):37-44.
44. Florescu I, Beuran M, Dimov R, et al; 307 Study Group. Efficacy and safety of tigecycline compared with vancomycin or linezolid for treatment of serious infections with methicillin-resistant Staphylococcus aureus or vancomycin-resistant enterococci: a Phase 3, multicentre, double-blind, randomized study. J Antimicrob Chemother. 2008;62(suppl 1):i17-i28.
45. Breedt J, Teras J, Gardovskis J, et al; Tigecycline 305 cSSSI Study Group. Safety and efficacy of tigecycline in treatment of skin and skin structure infections: results of a double-blind phase 3 comparison study with vancomycin-aztreonam. Antimicrob Agents Chemother. 2005;49(11):4658-4666. (Pubitemid 41552597)
46. Sacchidanand S, Penn RL, Embil JM, et al. Efficacy and safety of tigecycline monotherapy compared with vancomycin plus aztreonam in patients with complicated skin and skin structure infections: results from a phase 3, randomized, double-blind trial. Int J Infect Dis. 2005;9(5):251-261. (Pubitemid 41196869)
47. Fagon J, Patrick H, Haas DW, et al Nosocomial Pneumonia Group. Treatment of gram-positive nosocomial pneumonia: prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Am J Respir Crit Care Med. 2000;161(3, pt 1):753-762. (Pubitemid 30171727)
48. Raad I, Bompart F, Hachem R. Prospective, randomized dose-ranging open phase II pilot study of quinupristin/dalfopristin versus vancomycin in the treatment of catheter-related staphylococcal bacteremia. Eur J Clin Microbiol Infect Dis. 1999;18(3): 199-202. (Pubitemid 29527955)
49. Raad I, Darouiche R, Vazquez J, et al. Efficacy and safety of weekly dalbavancin therapy for catheter-related bloodstream infection caused by gram-positive pathogens. Clin Infect Dis. 2005;40(3):374-380. (Pubitemid 40216504)
50. Rubinstein E, Lalani T, Corey GR, et al ATTAIN Study Group. Telavancin versus vancomycin for hospital-acquired pneumonia due to gram-positive pathogens. Clin Infect Dis. 2011;52(1): 31-40.
51. Stryjewski ME, Graham DR, Wilson SE, et al Assessment of Telavancin in Complicated Skin and Skin-Structure Infections Study. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by gram-positive organisms. Clin Infect Dis. 2008;46(11):1683-1693. (Pubitemid 351706765)
52. Stryjewski ME, Chu VH, O'Riordan WD, et al; FAST 2 Investigator Group. Telavancin versus standard therapy for treatment of complicated skin and skin structure infections caused by gram-positive bacteria: FAST 2 study. Antimicrob Agents Chemother. 2006;50(3):862-867. (Pubitemid 43327787)
53. Stryjewski ME, O'Riordan WD, Lau WK, et al FAST Investigator Group. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis. 2005;40(11):1601-1607. (Pubitemid 40720810)
54. Sanofi-Aventis. Comparison of teicoplanin and vancomycin in initial empirical antibiotic regimen for febrile neutropenic patients. 2008. Trial NCT00454272. http://www.clinicalstudyresults. org/documents/company-study-8797- 0.pdf. Accessed January 13, 2010.
55. D'Antonio D, Staniscia T, Piccolomini R, et al. Addition of teicoplanin or vancomycin for the treatment of documented bacteremia due to gram-positive cocci in neutropenic patients with haematological malignancies: microbiological, clinical and economic evaluation. Chemotherapy. 2004;50(2):81-87. (Pubitemid 38813017)
56. Pham Dang C, Gouin F, Touchais S, Richard C, Potel G. The comparative costs of vancomycin treatment versus teicoplanin in osteoarticular infection caused by methicillin-resistant staphylococci [in French]. Pathol Biol (Paris). 2001;49(7):587-596. (Pubitemid 32917013)
57. Sidi V, Roilides E, Bibashi E, Gompakis N, Tsakiri A, Koliouskas D. Comparison of efficacy and safety of teicoplanin and vancomycin in children with antineoplastic therapy-associated febrile neutropenia and gram-positive bacteremia. J Chemother. 2000;12(4):326-331. (Pubitemid 30640386)
58. Rolston KV, Bodey GP, Chow AW. Prospective, double-blind, randomized trial of teicoplanin versus vancomycin for the therapy of vascular access-associated bacteremia caused by gram-positive pathogens. J Infect Chemother. 1999;5(4):208- 212.
59. Vázquez L, Encinas MP, Morín LS, et al. Randomized prospective study comparing cost-effectiveness of teicoplanin and vancomycin as second-line empiric therapy for infection in neutropenic patients. Haematologica. 1999;84(3):231-236. (Pubitemid 29476927)
60. Van Laethem Y, Hermans P, De Wit S, Goosens H, Clumeck N. Teicoplanin compared with vancomycin in methicillin-resistant Staphylococcus aureus infections: preliminary results. J Antimicrob Chemother. 1988;21(suppl A):81-87.
61. Nucci M, Biasoli I, Braggio S, et al. Ceftazidime plus amikacin plus teicoplanin or vancomycin in the empirical antibiotic therapy in febrile neutropenic cancer patients. Oncol Rep. 1998; 5(5):1205-1209. (Pubitemid 28372588)
62. Auperin A, Cappelli C, Benhamou E, et al. Teicoplanin or vancomycin in febrile neutropenic children with cancer: a randomized study on cost effectiveness. Med Mal Infect. 1997; 27:984-988. (Pubitemid 28034395)
63. Liu CY, Lee WS, Fung CP, et al. Comparative study of teicoplanin vs vancomycin for the treatment of methicillin-resistant Staphylococcus aureus bacteraemia. Clin Drug Investig. 1996;12: 80-87.
64. Figuera A, Tomás JF, Hernández L, et al. Imipenem combined with teicoplanin or vancomycin in the initial empirical treatment of febrile neutropenia: analysis of the primary response and of a global sequential strategy in 126 episodes. Rev Clin Esp. 1996;196(8):515-522.
65. Neville LO, Brumfitt W, Hamilton-Miller JMT, Hardingb I. Teicoplanin vs. vancomycin for the treatment of serious infections: a randomised trial. Int J Antimicrob Agents. 1995;5:187-193.
66. Rolston KV, Nguyen H, Amos G, Elting L, Fainstein V, Bodey GP. A randomized double-blind trial of vancomycin versus teicoplanin for the treatment of gram-positive bacteremia in patients with cancer. J Infect Dis. 1994;169(2):350-355. (Pubitemid 24045595)
67. Menichetti F, Martino P, Bucaneve G, et al Gimema Infection Program. Effects of teicoplanin and those of vancomycin in initial empirical antibiotic regimen for febrile, neutropenic patients with hematologic malignancies. Antimicrob Agents Chemother. 1994;38(9):2041-2046. (Pubitemid 24278798)
68. Charbonneau P, Harding I, Garaud JJ, Aubertin J, Brunet F, Domart Y. Teicoplanin: a well-tolerated and easily administered alternative to vancomycin for gram-positive infections in intensive care patients. Intensive Care Med. 1994;20(suppl 4): S35-S42.
69. Kureishi A, Jewesson PJ, Rubinger M, et al. Double-blind comparison of teicoplanin versus vancomycin in febrile neutropenic patients receiving concomitant tobramycin and piperacillin: effect on cyclosporine A-associated nephrotoxicity. Antimicrob Agents Chemother. 1991;35(11):2246-2252.
70. Van der Auwera P, Aoun M, Meunier F. Randomized study of vancomycin versus teicoplanin for the treatment of gram-positive bacterial infections in immunocompromised hosts. Antimicrob Agents Chemother. 1991;35(3):451-457.
71. Cony-Makhoul P, Brossard G, Marit G, Pellegrin JL, Texier-Maugein J, Reiffers J. A prospective study comparing vancomycin and teicoplanin as second-line empiric therapy for infection in neutropenic patients. Br J Haematol. 1990;76(suppl 2):35-40.
72. Gilbert DN, Wood CA, Kimbrough RC; The Infectious Diseases Consortium of Oregon. Failure of treatment with teicoplanin at 6 milligrams/kilogram/day in patients with Staphylococcus aureus intravascular infection. Antimicrob Agents Chemother. 1991;35(1):79-87.
73. Smith SR, Cheesbrough J, Spearing R, Davies JM. Randomized prospective study comparing vancomycin with teicoplanin in the treatment of infections associated with Hickman catheters. Antimicrob Agents Chemother. 1989;33(8):1193-1197. (Pubitemid 19191955)
74. Pertel PE, Eisenstein BI, Link AS, et al. The efficacy and safety of daptomycin vs. vancomycin for the treatment of cellulitis and erysipelas. Int J Clin Pract. 2009;63(3):368-375.
75. Katz DE, Lindfield KC, Steenbergen JN, et al. A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria. Int J Clin Pract. 2008;62(9): 1455-1464.
76. Rehm SJ, Boucher H, Levine D, et al. Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates. J Antimicrob Chemother. 2008;62(6):1413-1421.
77. Krievins D, Brandt R, Hawser S, Hadvary P, Islam K. Multicenter, randomized study of the efficacy and safety of intravenous iclaprim in complicated skin and skin structure infections. Antimicrob Agents Chemother. 2009;53(7):2834-2840.
78. Leibovici L, Falagas ME. Systematic reviews and meta-analyses in infectious diseases: how are they done and what are their strengths and limitations? Infect Dis Clin North Am. 2009;23(2): 181-194.
79. Siempos II, Vardakas KZ, Manta KG, Falagas ME. Carbapenems for the treatment of immunocompetent adult patients with nosocomial pneumonia. Eur Respir J. 2007;29(3):548-560. (Pubitemid 46372104)
80. Falagas ME, Siempos II, Papagelopoulos PJ, Vardakas KZ. Linezolid for the treatment of adults with bone and joint infections. Int J Antimicrob Agents. 2007;29(3):233-239. (Pubitemid 46240739)
81. Falagas ME, Manta KG, Ntziora F, Vardakas KZ. Linezolid for the treatment of patients with endocarditis: a systematic review of the published evidence. J Antimicrob Chemother. 2006; 58(2):273-280. (Pubitemid 44313381)
82. Wunderink RG, Niederman MS, Kollef MH, et al. Linezolid in methicillin-resistant staphylococcus aureus nosocomial pneumonia: a randomized, controlled study. Clin Infect Dis. 2012; 54(5):621-629.
83. Johnson and Johnson. Ceftobiprole versus linezolid plus ceftazidime for patients with nosocomial pneumonia. http:// filehosting.pharmacm.com/ DownloadService.ashx?client=CTR- JNJ-6051&studyid=635&filename=CR005032- CR005140-CSR. pdf. Accessed September 7, 2011.
84. Neuner EA, Ritchie DJ, Micek ST. New antibiotics for health-care- associated pneumonia. Semin Respir Crit Care Med. 2009; 30(1):92-101.
85. Freire AT, Melnyk V, Kim MJ, et al. Comparison of tigecycline with imipenem/cilastatin for the treatment of hospital-acquired pneumonia. Diagn Microbiol Infect Dis. 2010;68(2): 140-151.
86. Vardakas KZ, Samonis G, Chrysanthopoulou SA, Bliziotis IA, Falagas ME. The role of glycopeptides as part of the empirical treatment in febrile neutropenic patients: a meta-analysis of randomized controlled trials. Lancet Infect Dis. 2005;5(7):431-439. (Pubitemid 40846470)
87. Paul M, Borok S, Fraser A, Vidal L, Cohen M, Leibovici L. Additional anti-Gram-positive antibiotic treatment for febrile neutropenic cancer patients. Cochrane Database Syst Rev. 2005;(3):CD003914.
88. Chemaly RF, Hanmod SS, Jiang Y, et al. Tigecycline use in cancer patients with serious infections: a report on 110 cases from a single institution. Medicine (Baltimore). 2009;88(4):211- 220.
89. Bubalo JS, Munar MY, Cherala G, Hayes-Lattin B, Maziarz R. Daptomycin pharmacokinetics in adult oncology patients with neutropenic fever. Antimicrob Agents Chemother. 2009;53(2): 428-434.
90. Poutsiaka DD, Skiffington S, Miller KB, Hadley S, Snydman DR. Daptomycin in the treatment of vancomycin-resistant Enterococcus faecium bacteremia in neutropenic patients. J Infect. 2007;54(6):567-571. (Pubitemid 46731225)
91. Itani KM, Weigelt J, Li JZ, Duttagupta S. Linezolid reduces length of stay and duration of intravenous treatment compared with vancomycin for complicated skin and soft tissue infections due to suspected or proven methicillin-resistant Staphylococcus aureus (MRSA). Int J Antimicrob Agents. 2005; 26(6):442-448. (Pubitemid 41635493)
92. Vinken A, Li Z, Balan D, Rittenhouse B, Wilike R, Nathwani D. Economic evaluation of linezolid, flucloxacillin and vancomycin in the empirical treatment of cellulitis in UK hospitals: a decision analytical model. J Hosp Infect. 2001;49(suppl A):S13-S24.
93. Li JZ, Willke RJ, Rittenhouse BE, Rybak MJ. Effect of linezolid versus vancomycin on length of hospital stay in patients with complicated skin and soft tissue infections caused by known or suspected methicillin-resistant staphylococci: results from a randomized clinical trial. Surg Infect (Larchmt). 2003;4(1):57-70. (Pubitemid 36546749)
94. Vardakas KZ, Kioumis I, Falagas ME. Association of pharmacokinetic and pharmacodynamic aspects of linezolid with infection outcome. Curr Drug Metabol. 2009;10(1):2-12.
95. Falagas ME, Vardakas KZ. Benefit-risk assessment of linezolid for serious gram-positive bacterial infections. Drug Saf. 2008; 31(9):753-768.
96. Vardakas KZ, Ntziora F, Falagas ME. Linezolid: effectiveness and safety for approved and off-label indications. Expert Opin Pharmacother. 2007;8(14):2381-2400. (Pubitemid 350017285)
97. Falagas ME, Vardakas KZ, Samonis G. Decreasing the incidence and impact of infections in neutropenic patients: evidence from meta-analyses of randomized controlled trials. Curr Med Res Opin. 2008;24(1):215-235. (Pubitemid 351160254)